Pharvaris Valuation
Is 9EN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9EN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 9EN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 9EN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9EN?
Key metric: As 9EN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 9EN's PB Ratio? | |
|---|---|
| PB Ratio | 4.2x |
| Book | €296.79m |
| Market Cap | €1.23b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -7.1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 9EN's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.2x | ||
DMP Dermapharm Holding | 3.4x | 18.1% | €2.0b |
PSG PharmaSGP Holding | 9.5x | 13.9% | €304.6m |
93M1 MPH Health Care | 0.3x | -65.7% | €102.8m |
2FJ0 Pierrel | 3.6x | n/a | €92.8m |
9EN Pharvaris | 4.2x | 10.1% | €1.3b |
Price-To-Book vs Peers: 9EN is expensive based on its Price-To-Book Ratio (4.2x) compared to the peer average (4.2x).
Price to Book Ratio vs Industry
How does 9EN's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 11 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: 9EN is expensive based on its Price-To-Book Ratio (4.2x) compared to the European Pharmaceuticals industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is 9EN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 4.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 9EN's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €21.80 | €33.10 +51.8% | 30.8% | €45.12 | €13.27 | n/a | 7 |
| Nov ’25 | €22.00 | €32.17 +46.2% | 31.1% | €45.12 | €12.74 | n/a | 7 |
| Oct ’25 | €16.00 | €31.88 +99.3% | 31.4% | €45.12 | €12.74 | n/a | 7 |
| Sep ’25 | €16.10 | €29.84 +85.3% | 32.5% | €45.35 | €12.74 | n/a | 6 |
| Aug ’25 | €14.30 | €31.18 +118.0% | 32.2% | €45.95 | €12.07 | n/a | 6 |
| Jul ’25 | €17.20 | €30.76 +78.9% | 32.2% | €45.95 | €12.07 | n/a | 6 |
| Jun ’25 | €17.00 | €30.84 +81.4% | 32.5% | €46.41 | €12.07 | n/a | 6 |
| May ’25 | €22.40 | €31.04 +38.6% | 32.7% | €46.69 | €11.94 | n/a | 6 |
| Apr ’25 | €21.20 | €31.32 +47.8% | 31.3% | €45.07 | €11.94 | n/a | 6 |
| Mar ’25 | €21.40 | €31.51 +47.2% | 31.2% | €45.17 | €11.94 | n/a | 6 |
| Feb ’25 | €27.00 | €28.98 +7.3% | 37.3% | €45.00 | €11.94 | n/a | 7 |
| Jan ’25 | €25.00 | €27.28 +9.1% | 35.4% | €37.06 | €10.20 | n/a | 7 |
| Dec ’24 | €15.80 | €20.42 +29.3% | 32.6% | €29.49 | €7.48 | n/a | 7 |
| Nov ’24 | €15.80 | €21.08 +33.4% | 34.5% | €31.26 | €7.33 | €22.00 | 7 |
| Oct ’24 | €19.10 | €20.84 +9.1% | 34.5% | €31.26 | €7.33 | €16.00 | 7 |
| Sep ’24 | €18.90 | €20.06 +6.1% | 37.3% | €31.26 | €7.33 | €16.10 | 6 |
| Aug ’24 | €15.20 | €15.83 +4.1% | 38.6% | €23.73 | €7.37 | €14.30 | 6 |
| Jul ’24 | €14.00 | €15.88 +13.4% | 38.4% | €23.73 | €7.37 | €17.20 | 6 |
| Jun ’24 | €8.20 | €14.67 +78.8% | 34.8% | €22.17 | €7.37 | €17.00 | 6 |
| May ’24 | €8.30 | €14.85 +79.0% | 35.1% | €22.77 | €7.59 | €22.40 | 6 |
| Apr ’24 | €7.35 | €15.51 +111.0% | 36.9% | €22.77 | €7.59 | €21.20 | 6 |
| Mar ’24 | €7.65 | €15.51 +102.7% | 36.9% | €22.77 | €7.59 | €21.40 | 6 |
| Feb ’24 | €8.40 | €15.74 +87.4% | 36.6% | €22.77 | €7.59 | €27.00 | 6 |
| Jan ’24 | €10.30 | €15.82 +53.6% | 35.7% | €22.77 | €7.59 | €25.00 | 6 |
| Dec ’23 | €1.97 | €15.26 +674.5% | 38.5% | €21.95 | €5.12 | €15.80 | 6 |
| Nov ’23 | €4.24 | €16.65 +292.7% | 24.0% | €21.95 | €10.31 | €15.80 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.55
7D
2.0%
1Y
95.6%
Collegium Pharmaceutical
US$993.0m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.20
7D
5.0%
1Y
23.7%
Pharming Group
€478.2m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.72
7D
1.8%
1Y
-31.2%